ClinicalTrials.gg
RecruitingNCT05610878Updated Dec 31, 2024

Efficacy of Preconditioned Adipose-Derived Stem Cells in Fat Grafting

A Phase 1 interventional study of Cultured ASCs enrichment fat grafting and Curcumin-preconditioned ASCs enrichment fat grafting in Romberg Disease, Craniofacial Microsomia and Burn Scar, sponsored by University of the Punjab. Recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2024-12-31.

Sponsored by University of the Punjab · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 11 months ago, but the record still lists the study as recruiting.
  • Registered 1 year 11 months after the study started (first participant enrolled Nov 2020, registered Oct 2022).
  • Started Nov 2020; still recruiting 6 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

The aim of this study is to evaluate the comparison of therapeutic potential of curcumin preconditioned adipose derived stem cells (ASCs) enrichment fat grafting, naïve ASCs enrichment fat grafting and conventional fat grafting to correct facial contour deformities that cause aesthetic complications in patients.

Read the detailed description

Human subcutaneous adipose tissue along informed consents will be collected in a lipoaspirate container or 20 cc B.D syringes under the sterilized conditions during the surgery. Fat aspirate collection will be based on certain selection criteria including pre-requisitioning non-diabetic, negative viral status patients. Adipose derived stem cells (ASCs) will be isolated from adipose tissue under sterile aseptic conditions. Firstly, the lipoaspirate container will be opened in the biosafety cabinet and drain off the blood carefully with the help of serological pipette. Then, fat will be washed thrice with 1X phosphate buffer saline (PBS) containing antibiotic and anti-mycotic solution, in order to get rid of blood vessels, hair and other type of connective tissue. After that, the tissue will be enzymatically digested with collagenase type I solution (1mg/ml prepared in Low Glucose Dulbecco's Modified Eagle Medium (LG-DMEM) and incubate for 45 minutes at 37°C on a shaker. After digestion, the enzyme will be inactivated by LG-DMEM augmented with 5% freshly isolated human serum and spin at 1200 rpm for 10 minutes. After centrifugation, fat will be discarded and the infranatant will be passed through 100 µm cell strainers to remove the debris. The filtrate will be centrifuged again for 1200rpm for 8 minutes. Pellet will be resuspended and plated in a sterile T-75 cm2 flask containing 10 ml LG-DMEM supplemented with 5% human serum. The flask will be placed in a humidified incubator at 37°C, 5% carbon dioxide (CO2). The media will be replenished after every third day until the cells got 80-90 % confluency. Cells of P2-P3 stage will be used in this study for immunocytochemistry, and intervention as well. For preconditioning, ASCs will be incubated with curcumin preconditioned medium for 24 h. Cell sterility and viability will be assessed prior to transplantation. For transplantation, 1,00,000 cells per ml of fat will be mixed, transferred to 10 cc syringes and injected at deformity site. Amount of fat will be predetermined by the clinician on the basis of facial asymmetry.

02

Conditions studied

  • Romberg Disease
  • Craniofacial Microsomia
  • Burn Scar
  • Post-Traumatic Scar (Disorder)

Keywords

  • Facial deformities
  • Fat grafting
  • Adipose derived stem cells
  • Preconditioning
03

In context

Lead sponsor

University of the Punjab is the lead sponsor of 20 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18-50 years (male or female)
  • Body-mass index 20-30 kg/m²
  • Suitable for liposuction as assessed by the expected cosmetic results
  • Provided signed

Exclusion criteria

Exclusion criteria

  • Systemic disorders include diseases, hemorrhagic diseases, bone marrow aplasia, sepsis, cancer, and others
  • Local disorders include acne, infections and others
  • Risk factors include smoking, uncompensated diabetes, hypertension, and allergy to the drugs used for general anesthesia
  • Microbiological contamination of either the cell culture or the transplanted tissue
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
24 participants (estimated)

Study arms

  • Experimental
    Cultured ASCs enrichment fat grafting

    Fat graft will be supplemented with naïve ASCs

    Biological: Cultured ASCs enrichment fat grafting

  • Experimental
    Curcumin-preconditioned ASCs enrichment fat grafting

    Fat graft will be augmented with curcumin preconditioned ASCs

    Biological: Curcumin-preconditioned ASCs enrichment fat grafting

  • Active comparator
    conventional fat grafting

    Fat graft will not be supplemented with ex-vivo expanded ASCs

    Other: Conventional fat grafting

Interventions

  • BiologicalCultured ASCs enrichment fat grafting

    Patients will undergo conventional fat harvesting. Harvested fat will be mixed with cultured ASCs and grafted into recipient site with 1,00,000 cells/ml injected fat

  • BiologicalCurcumin-preconditioned ASCs enrichment fat grafting

    Patients will undergo conventional fat harvesting. Harvested fat will be mixed with cultured ASCs preconditioned with curcumin and grafted into recipient site with 1,00,000 cells/ml injected fat

  • OtherConventional fat grafting

    Patients will undergo conventional fat harvesting and grafting of fat into recipient site

06

What researchers measure

Primary outcomes

  1. Volumetric change in facial tissue by ultrasonography

    Volumetric evaluation of treated area will be done by measuring the thickness of subcutaneous tissue (in millimeters) by using baseline B mode ultrasound device. Volumetric evaluation of treated area will be done by measuring the thickness of subcutaneous tissue (in millimeters) before transplantation, 1 week after transplantation then after 3, 6 and 9 months by using baseline B mode ultrasound device.

    Time frame: 9 months

Secondary outcomes

  1. Patient Assessment

    Patients will be interviewed and pre-and post-operatively and digital images will be taken until 9 months of follow up.

    Time frame: 9 months

  2. Surgeon Assessment

    Patients will be visually inspected for facial volume by two qualified plastic surgeons unaware of treatment after grafting to check whether curcumin pretreatment have effect on MSCs origin of ASCs.

    Time frame: 9 months

07

Study locations

1 of 1 sites recruiting
  • Stem Cell Laboratory, Jinnah Burn and Reconstructive Surgery Center (JB&RSC)
    Lahore, Punjab 54550, Pakistan
    Recruiting
    • Dr. Moazzam Nazeer Tarar, Plastic Surgeon MBBS/ FRCS · Contactmntarar@gmail.com · +92-300-8423139
08

References and documents

Publications

  • Matsumoto D, Sato K, Gonda K, Takaki Y, Shigeura T, Sato T, Aiba-Kojima E, Iizuka F, Inoue K, Suga H, Yoshimura K. Cell-assisted lipotransfer: supportive use of human adipose-derived cells for soft tissue augmentation with lipoinjection. Tissue Eng. 2006 Dec;12(12):3375-82. doi: 10.1089/ten.2006.12.3375. PubMed 17518674 ↗
  • Bashir MM, Sohail M, Ahmad FJ, Choudhery MS. Preenrichment with Adipose Tissue-Derived Stem Cells Improves Fat Graft Retention in Patients with Contour Deformities of the Face. Stem Cells Int. 2019 Nov 20;2019:5146594. doi: 10.1155/2019/5146594. eCollection 2019. PubMed 31827528 ↗
  • Ghufran H, Mehmood A, Azam M, Butt H, Ramzan A, Yousaf MA, Ejaz A, Tarar MN, Riazuddin S. Curcumin preconditioned human adipose derived stem cells co-transplanted with platelet rich plasma improve wound healing in diabetic rats. Life Sci. 2020 Sep 15;257:118091. doi: 10.1016/j.lfs.2020.118091. Epub 2020 Jul 12. PubMed 32668325 ↗
  • Bourne DA, Egro FM, Bliley J, James I, Haas GL, Meyer EM, Donnenberg V, Donnenberg AD, Branstetter B, Coleman S, Rubin JP. Stem Cell Therapy Enriched Fat Grafting for the Reconstruction of Craniofacial Deficits. Plast Reconstr Surg Glob Open. 2023 Jun 19;11(6):e5056. doi: 10.1097/GOX.0000000000005056. eCollection 2023 Jun. PubMed 37342306 ↗
  • Cao Z, Li H, Wang ZH, Liang XQ. High-Density Fat Grafting Assisted Stromal Vascular Fraction Gel in Facial Deformities. J Craniofac Surg. 2022 Jan-Feb 01;33(1):108-111. doi: 10.1097/SCS.0000000000008038. PubMed 34519702 ↗
  • Wang C, Long X, Si L, Chen B, Zhang Y, Sun T, Zhang X, Zhao RC, Wang X. A pilot study on ex vivo expanded autologous adipose-derived stem cells of improving fat retention in localized scleroderma patients. Stem Cells Transl Med. 2021 Aug;10(8):1148-1156. doi: 10.1002/sctm.20-0419. Epub 2021 Apr 19. PubMed 33871949 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Nov 2020 (actual). Primary completion is estimated for Dec 2025, 61 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2022
First posted
Nov 9, 2022
StartActual
Nov 20, 2020
Primary completionEst.
Dec 2025
CompletionEst.
Dec 2025
Last update
Dec 31, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 31, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05610878
Lead sponsor
University of the Punjab
Collaborators
Centre of Excellence in Molecular Biology, University of the Punjab, Lahore, Higher Education Commission (Pakistan), Jinnah Burn and Reconstructive Surgery Centre, Lahore
Responsible party
Azra Mehmood (Associate Professor, University of the Punjab) — Principal investigator
First posted
Nov 9, 2022
Start date
Nov 20, 2020
Primary completion
Dec 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Dec 31, 2024

Study contacts

Azra Mehmood, PhD
Contact
azra_mehmood@hotmail.com
+92-333-4107008
Amna Arif, M.Phil.
Contact
amnaarif.qureshi@gmail.com
+92-333-4161068
Azra Mehmood, PhD
principal investigator · Center of Excellence in Molecular Biology (CEMB), University of the Punjab, Lahore
Sheikh Riazuddin, PhD
study director · Jinnah Burn and Reconstructive Surgery Center (JB&RSC), Lahore

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion